Novartis opposed the Australian designation of Obvieline’s International Registration for SYNECTHA, covering pharmaceutical goods in Class 5.
The opposition was based largely on the opponent’s prior SYNACTHEN registration, which also...
Novartis opposed the Australian designation of Obvieline’s International Registration for SYNECTHA, covering pharmaceutical goods in Class 5.
The opposition was...